NCT06643780View on ClinicalTrials.gov

RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis

PHASE4RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

April 30, 2027

Study Completion Date

October 31, 2027

Conditions
Sarcopenia in Elderly
Interventions
DRUG

Denosumab

60mg subcutaneous Denosumab (1mL solution) every 6 months and intravenous placebo (100mL normal saline) once yearly

DRUG

Zolendronic Acid

5mg intravenous Zoledronic Acid (100mL solution) once yearly and subcutaneous placebo (1mL normal saline) every 6 months

Trial Locations (1)

Unknown

RECRUITING

The Chinese University of Hong Kong, Hong Kong

All Listed Sponsors
collaborator

Chinese University of Hong Kong

OTHER

lead

Prince of Wales Hospital, Shatin, Hong Kong

OTHER